Determination of Prekallikrein in Plasma by Means of a Chromogenic Tripeptide Substrate for Plasma Kallikrein
A method for plasma prekallikrein determination utilizing a chromo-genic tripeptide substrate is presented. The method has a good reproducibility and can easily be automized. Several parameters have been optimized. By using mixtures of deficient plasmas and pooled normal plasma or purified factors it was proved that prekallikrein was the factor determined and that more than 10% (of normal plasma concentration) of FXII and HMW kininogen were essential for the activation of prekallikrein in our method. Further experiments showed that the method was fairly selective and was not influenced by inhibitors present in normal plasma. The later finding was attributed to the high dilution of plasma made possible by using a potent activator and a sensitive substrate.
KeywordsDextran Sulphate Sodium Ellagic Acid Normal Plasma Dextran Sulphate Flufenamic Acid
Unable to display preview. Download preview PDF.
- 1.Amundsen, E. and Svendsen, L.: A new method for plasma kallikrein utilizing a synthetic chromogenic substrate. In: New methods for the analysis of coagulation using chromogenic substrates. Ed. I. Witt, Walter de Gruyter. p. 211, 1977.Google Scholar
- 2.Aurell, L., Friberger, P., Karlsson, G. and Claeson, G.: A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb. Res. II: 595–609, 1977.Google Scholar
- 8.Friberger, P., Knos, M., Gustafsson, S., Aurell, L. and Claeson, G.: A new specific substrate for the determination of plasmin activity. In: Chromogenic Substrates. Ed. V.V. Kakkar. Churchill Livingstone. In press.Google Scholar
- 1l.Kaplan, A.P., Meier, H.L. and Mandle, R.: The Hageman factor dependent pathway of coagulation, fibrinolysis and kinin generation. Seminars in Thrombosis and Haemostasis 3: 1–26, 1976.Google Scholar
- 12.Kluft, C.: Blood Fibrinolysis. Preactivators and activators in human plasma. Thesis. Dutch Efficiency Bureau-Pijnacker. p. 104, 1978.Google Scholar
- 14.Schreiber, A.D.: Plasma inhibitors of the Hageman factor dependent pathways. Seminars in Thrombosis and Haemostasis 3: 43–51, 1976.Google Scholar